Breaking News

Financial Report: Covance

May 2, 2014

Late-Stage revenues up 8% in the quarter

Covance

1Q Revenues: $666.3 million (+5%)

1Q Earnings: $50.8 million (+6%)

Comments: Late-Stage Development revenues were up 8% to $402 million in the quarter. Central labs and clinical development were up 11% and 6%, respectively, offsetting a decline in market access services. Early Development revenue was up 5% to $218 million, with growth in clinical pharmacology, research products, and nutritional chemistry offsetting the sale of the Seattle genomics lab and declines in toxicology and discovery support. 
blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain

  • API Sourcing Trends

    API Sourcing Trends

    Kristin Brooks, Contract Pharma||March 19, 2015
    Ed Price of PCI Synthesis addresses trends, regulatory and supply chain hurdles, and quality concerns